Format

Send to

Choose Destination
Clin J Oncol Nurs. 2011 Oct;15(5):E83-9. doi: 10.1188/11.CJON.E83-E89.

Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors.

Author information

1
Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. apilotte@partners.org

Abstract

Mammalian target of rapamycin (mTOR) inhibitors are a class of targeted cancer therapeutic agents with clinical benefit for multiple tumor types. Oral ulcerations are a common side effect of mTOR inhibitors; however, the clinical findings resemble aphthous stomatitis rather than the mucositis seen with chemotherapy. Consequently, the appearance of aphthous-like oral ulcerations has been referred to as mTOR inhibitor-associated stomatitis (mIAS). The severity of mIAS can be minimized by following common preventive steps and initiating treatment at the first sign of mouth discomfort, thereby reducing the likelihood of treatment discontinuation. mIAS can be managed through prophylactic measures, such as patient education in oral hygiene and avoidance of triggers. Patients who develop mIAS may be treated topically using rinses or other local therapies, including corticosteroids. In severe cases, dose modifications may be required. Oncology nurses have an important role in the management of patients with cancer and are well positioned to offer strategies for minimizing the occurrence and impact of mIAS.

PMID:
21951751
DOI:
10.1188/11.CJON.E83-E89
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Oncology Nursing Society
Loading ...
Support Center